Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Other Non-Current Assets (2019 - 2026)

Immunovant filings provide 4 years of Other Non-Current Assets readings, the most recent being $8.9 million for Q4 2025.

  • Quarterly Other Non-Current Assets rose 17.13% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2025, up 17.13% year-over-year, with the annual reading at $7.6 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets hit $8.9 million in Q4 2025 for Immunovant, up from $8.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $8.9 million in Q2 2025 and bottomed at $7.6 million in Q4 2024.